A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies

Solid Tumor, Adult Clinical Trial

Official title:

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04014257
• Other study ID #: NOV160101-101
• Status: Completed
• Phase: Phase 1
• Start date: August 9, 2019
• Est. completion date: January 29, 2021

Study information

• Verified date: August 2021
• Source: Handok Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a first-in-human (FIH) study which is required to understand the PK characteristics, MTD, and safety profile of NOV1601(CHC2014) in subjects with solid organ malignancies.

Description:

This is the first-in-human, Phase 1, open-label, multicenter, dose-escalation study to investigate the safety, tolerability, PK, and clinical activity of NOV1601(CHC2014) in subjects with solid organ malignancies. The primary goal of the study is to determine the RP2D of NOV1601(CHC2014) in adult subjects with solid organ malignancies. Dose escalation will follow a 3+3 design and will be based on prior cohort review. There will be 2 branches of the dosing schedule, once a day(QD) and twice daily(BID).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: January 29, 2021
• Est. primary completion date: January 22, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria(partial):

• Pathological confirmation of malignancy and evidence of metastatic or surgically unresectable disease
• At least one evaluable or measurable lesion should be present and identified according to Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1 or Response Assessment in Neuro-Oncology(RANO)
• Relapse after or refractory to systemic drug therapy to malignancy, at least one regimen of cytotoxic chemotherapy, kinase inhibitors including tyrosine kinase inhibitors or immunotherapy which is considered as standard of care if there is no standard regimen recommended, then no experience of systemic drug therapy is acceptable
• Patients with primary central nervous system(CNS) tumors or metastasis, if they have been neurologically stable
• Symptoms should be under control by stable dose of glucocorticoids and analgesic drugs for symptom control at least 2 weeks prior to starting the treatment
• Stable dose of glucocorticoids and analgesic drugs for symptom control should be maintained throughout the study
• Subjects should be off from radiotherapy for at least 14 days prior to the start of study treatment(C1D1) without symptom aggravation

Exclusion Criteria(partial):

• Prior high-dose chemotherapy requiring hematopoietic stem cell transplantation
• History or evidence of suspicious leptomeningeal disease
• Previous surgery of gastrectomy, gastrostomy or any medical condition which interferes with oral ingestion of capsule
• Indwelling percutaneous drainage of bile and chest tube
• Evidence of or suspicious symptomatic spinal cord compression, unless appropriately treated and neurologically stable off glucocorticoid for at least 2 weeks

Related Conditions & MeSH terms

• Neoplasms
• Phase 1
• Solid Tumor, Adult

Intervention

Drug:
• NOV1601(CHC2014)
a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)

Locations

Country	Name	City	State
Korea, Republic of	National Cancer Center	Goyang	Gyeonggi-do
Korea, Republic of	CHA Bundang Medical Center	Seongnam	Gyeonggi-do
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Severance Hospital	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
Handok Inc.	CMG Pharmaceutical Co. Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the recommended Phase 2 dose(RP2D) or the maximum tolerated dose(MTD) of NOV1601	MTD will be the RP2D, based on the pharmacokinetic(PK) profiles and safety profiles as assessed by the Safety Monitoring Committee (SMC).	Subjects will be treated and observed for dose-limiting toxicity(DLT) through the end of the first cycle (Days 1-28).
Secondary	Number of participants with treatment-related adverse events(TEAE) and serious adverse events(SAE)	Each adverse event will be coded using the Medical Dictionary for Regulatory Activities(version 20.0) classification system. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.	Maximum 2 years